- * Male or female participants, \>=12 years of age (\>= 18 years of age for participants at German sites only), undergoing HCT for hematological malignancies, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.
- * Planned myeloablative conditioning regimen.
- * Participants must have a related or unrelated donor as follows:
- * Related donor must be a 6 / 6 match for human leukocyte antigen (HLA)-A, -B, at intermediate (or higher) resolution, and -DR beta 1 (DRB1) at high resolution using deoxyribonucleic acid (DNA)-based typing.
- * Unrelated donor must be 7 / 8 or 8 / 8 match for HLA-A, -B, and -C at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing.
Acute-graft-versus-host Disease
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
NCT03805789 | PHASE 2 | INTERVENTIONAL
This study is a phase 2 / 3 prospective, double-blind, randomized, multicenter, placebo-controlled study for prevention of acute GVHD (aGVHD) in participants undergoing an unrelated (matched or single allele mismatched) or matched related allogeneic hematopoietic cell transplantation (HCT).
Trial Information
If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
HonorHealth Scottsdale Shea Medical Center
Scottsdale,Arizona,United States,85258
Johns Hopkins Hospital
St. Petersburg,Florida,United States,33701
Emory University
Atlanta,Georgia,United States,30322
University of Kansas Cancer Center
Westwood,Kansas,United States,66205
Dana Farber Cancer Institute
Boston,Massachusetts,United States,02215
University of Michigan Medical Center
Ann Arbor,Michigan,United States,48109
Duke University Medical Center
Durham,North Carolina,United States,27705
University Hospital Cleveland Medical Center
Cleveland,Ohio,United States,44106
The University of TexasMD Anderson Cancer Center
San Antonio,Texas,United States,77030
University of Utah Primary Children's Hospital
Salt Lake City,Utah,United States,84113
University of Virginia Health System
Charlottesville,Virginia,United States,22903
Fred Hutchinson Cancer Research Center
Seattle,Washington,United States,98109
Royal Brisbane and Women's Hospital
Herston,Queenland,Australia,4029
Uniklinik Kln, lnnere Mediz
Cologne,Queenland,Germany,50937
University Hospital Catania
Calabria,Catania,Italy,95123
Grande Ospedale Metropolitano BianchiMelacrinoMorelli
Calabria,Catania,Italy,89133
Anjo Kosei Hospital
Anjo-shi,Catania,Japan,4668602
Tokyo Metropolitan Komagome Hospital
Bunkyō City,Catania,Japan,1138677
Hiroshima University Kasumi Campus
Hiroshima,Catania,Japan,7348551
Aichi Medical Center Nagoya Daiichi Hospital
Nagoya,Catania,Japan,4538511
Nagoya University Hospital
Nagoya,Catania,Japan,4668550
Okayama University Hospital
Okayama,Catania,Japan,71008558
Osaka International Cancer Institute
Osaka,Catania,Japan,5418567
Osaka Metropolitan University Hospital
Osaka,Catania,Japan,5458586
Hokkaido University Hospital
Sapporo,Catania,Japan,0608648
INJE University Haeundae Paik Hospital
Busan,Catania,South Korea,48108
Pusan National University Hospital
Busan,Catania,South Korea,49241
Gachon University Gil Medical Center
Incheon,Catania,South Korea,21565
Seoul National University Hospital
Seoul,Catania,South Korea,03080
Hospital Universitario Valle de Hebron
Barcelona,Catania,Spain,08035
Marqus de Valdecilla University Hospital
Barcelona,Catania,Spain,39008
Salamanca University Hospital
Salamanca,Catania,Spain,37007
Ankara Abdurrahman Yurtaslan
Ankara,Catania,Turkey (Türkiye),06200
Turgut Ozal Medicine Center
Battalgazi,Catania,Turkey (Türkiye),44280
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov